Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Double-Masked, Randomized, 3-Arm Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTXTKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy

NCT07235085 is registered in ClinicalTrials.gov with Ocular Therapeutix, Inc. as lead sponsor.

NCT NCT07235085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07235085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Double-Masked, Randomized, 3-Arm Parallel Group Study to Evaluate the Efficacy and Safety of Intravitreal OTXTKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
Lead sponsor
Ocular Therapeutix, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
November 17, 2025
Completion date
March 31, 2027
Enrollment
930 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-proliferative diabetic retinopathy